Skip to main content
BMC Medical Co., Ltd. logo

BMC Medical Co., Ltd. — Investor Relations & Filings

Ticker · 301367 ISIN · CNE100005WQ4 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 528 across all filing types
Latest filing 2026-01-29 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 301367

About BMC Medical Co., Ltd.

https://www.bmc-medical.com

BMC Medical Co., Ltd. specializes in the development and distribution of diagnostic and therapeutic solutions for sleep-disordered breathing and chronic respiratory conditions. The company’s core product portfolio includes continuous positive airway pressure (CPAP) devices, bilevel positive airway pressure (BPAP) systems, and high-flow oxygen therapy equipment. These are complemented by a range of patient interfaces, including nasal, pillow, and full-face masks. BMC integrates digital health capabilities through cloud-based management platforms, enabling remote data analysis and patient monitoring. By focusing on technical innovation and clinical efficacy, the company provides integrated respiratory care systems designed to improve patient compliance and therapeutic outcomes for conditions such as obstructive sleep apnea and chronic obstructive pulmonary disease.

Recent filings

Filing Released Lang Actions
关于与关联方共同投资暨关联交易进展的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Beijing Ruimait Medical Technology Co., Ltd. regarding progress on a related party joint investment and related transactions. It details the establishment and registration of investment entities and provides business license information. The document is short (1298 characters) and focuses on corporate investment and related party transactions, not on financial results, management changes, or regulatory filings. It does not contain financial statements or detailed financial data. This fits best under Capital/Financing Update (CAP) as it relates to company fundraising and capital structure changes through joint investment with related parties.
2026-01-29 Chinese
2025年度业绩预告
Earnings Release Classification · 95% confidence The document is a performance forecast for the fiscal year 2025, providing estimated net profit and revenue figures. It explicitly states that the data is preliminary, unaudited, and subject to final audit results in the annual report. The document is short (1032 characters) and serves as an announcement of expected financial results rather than a full financial report. It does not contain actual audited financial statements or detailed financial analysis. Therefore, it is best classified as an Earnings Release (ER), which covers initial announcements of quarterly or periodical financial results with key highlights only. FY 2025
2026-01-19 Chinese
关于特定股东、持股5%以上股东及其一致行动人减持股份的预披露公告
Major Shareholding Notification Classification · 100% confidence The document is a detailed announcement regarding a planned reduction in shareholding by specific shareholders holding 5% or more of the company's shares. It includes information about the shareholders, the number and percentage of shares to be reduced, the methods and timing of the reduction, shareholder commitments, and regulatory compliance. There is no financial data, earnings information, or management discussion of results. The document is not a report but an announcement about shareholding changes by major shareholders. This fits the definition of a Major Shareholding Notification (MRQ). The document length and content confirm it is not a brief notice or a report publication announcement but a substantive notification about shareholding changes.
2026-01-16 Chinese
第三届董事会第十七次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolutions passed at the 17th meeting of the third board of directors of Beijing Ruimait Medical Technology Co., Ltd. It details the meeting attendance, the approval of a related party investment transaction, and the voting results. It references compliance with regulatory rules and mentions related documents filed elsewhere. The document is short (1008 characters) and serves as a formal announcement of board decisions rather than a full management report or financial statement. Therefore, it fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors.
2026-01-06 Chinese
关于与关联方共同投资暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Beijing Ruimait Medical Technology Co., Ltd. regarding a related-party transaction involving joint investment with related parties to establish a joint venture company. It details the transaction overview, parties involved, investment structure, governance, and approvals from the board and independent directors. The document is a formal disclosure of a corporate transaction and related-party dealings, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial analysis but focuses on the announcement of a capital investment and related-party transaction. This fits the definition of a Capital/Financing Update (CAP) as it updates on company fundraising and capital structure changes through joint investment with related parties.
2026-01-06 Chinese
中国国际金融股份有限公司关于北京瑞迈特医疗科技股份有限公司与关联方共同投资暨关联交易的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from a sponsoring institution (China International Capital Corporation Limited) regarding a related-party joint investment transaction involving Beijing Ruimaite Medical Technology Co., Ltd. It includes comprehensive information about the related parties, the joint venture company, investment terms, governance, risk assessment, and internal approval procedures. The document references compliance with Shenzhen Stock Exchange rules and includes independent director and board meeting approvals. It is not a financial report, earnings release, or regulatory filing per se, but a formal verification opinion related to a specific transaction. This type of document is best classified as a Regulatory Filing (RNS) because it is a compliance and verification statement related to a transaction and does not fit other categories like Capital/Financing Update or M&A Activity, as it is about a related-party investment and includes a formal opinion from the sponsor. The document length and detail also exclude it from being a mere announcement or report publication notice.
2026-01-06 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.